Navigation Links
InfraReDx Completes $21 Million Equity Financing

BURLINGTON, Mass., Oct. 12 /PRNewswire/ -- InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced the completion of a $21 million equity financing. This round of investment attracted new institutions as well as existing investors, including Sanderling Ventures. Funds from the financing are being used to support the full commercial launch of the LipiScan™ IVUS Coronary Imaging System, the world's first and only intravascular imaging system that combines and co-registers grayscale intravascular ultrasound (IVUS) with InfraReDx's proprietary near infrared (NIR) spectroscopy lipid core plaque (LCP) detection technology.

"We are pleased to provide this novel diagnostic tool for the care of coronary patients. Our existing investors have been very supportive of the effort to develop LipiScan IVUS and the unique capabilities of the system have been instrumental in attracting the support of new investors, as well," said James E. Muller, M.D., founder and chief executive officer of InfraReDx. "The LipiScan IVUS system will enable interventional cardiologists to accurately and rapidly identify the lipid core plaques that complicate stenting and are believed to be the major cause of heart attacks. Our full commercial launch will bring this important and eagerly awaited interventional imaging technology to leading catheterization labs in the U.S. this year. It will be available in Europe in 2011."

The LipiScan IVUS system employs proprietary optical imaging technology to overcome the challenges of heart motion, blood interference, and vascular access to perform NIR spectroscopic analysis of the vessel and produce a chemical map of lipid-core plaque called a Chemogram™. The system provides physicians with a traditional IVUS image that shows plaque location, degree of stenosis and degree of stent expansion. At the same time optical data are recorded that permit identification, and co-localization of lipid core plaques. This innovative multi-modality analysis is accomplished directly in the catheterization laboratory during the coronary intervention via a single catheter pullback procedure. The data are immediately available to the physician to help guide the stenting procedure.

"As a long-term investor in InfraReDx, we are pleased with the Company's progress and are committed to supporting its successful commercial launch of the LipiScan IVUS system," said Robert McNeil, Ph.D., managing director of Sanderling Ventures and co-chairman of the InfraReDx board of directors. "Today, there is a critical need for better cardiac imaging technologies to accurately identify lipid core plaques in order to improve stenting procedural outcomes and, ultimately, to reduce the incidence of heart attacks and other coronary events. With this launch of the LipiScan IVUS system, InfraReDx is making available to cardiologists throughout the U.S. a significant and proven advance in the field of intravascular imaging. We believe that InfraReDx is very well positioned to capture key market share in the intravascular imaging market."  

About InfraReDx, Inc.InfraReDx, Inc. is a privately funded medical device company improving patient care through the development and commercialization of intelligent imaging technologies to improve the diagnosis and treatment of coronary artery disease. InfraReDx's LipiScan™ IVUS Coronary Imaging System is the first and only available catheter to combine both near-infrared spectroscopy (NIR) and intravascular ultrasound (IVUS) technologies to both visualize and characterize the intracoronary lipid core plaques (LCP) suspected of causing the majority of heart attacks. Founded in 1998, InfraReDx is headquartered in Burlington, Massachusetts. For more information, visit  Contacts:Susan Heins (media)

Grant FrazierPure Communications, Inc.

Vice President of Marketing864-286-9597


SOURCE InfraReDx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InfraReDxs New LipiScan™ IVUS Coronary Imaging System to be Highlighted at TCT 2010
2. InfraReDxs LipiScan(TM) Coronary Imaging System for Identification of Lipid Core Plaque to be Highlighted at 59th Annual Scientific Session of the American College of Cardiology
3. InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundations (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting
4. First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System
5. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
6. Ocular Therapeutix Completes Proof of Principle Study with Moxifloxacin-Loaded Punctum Plugs
7. Apollo Endosurgery Completes First Clinical Case with Newly-Launched FlexShears™ Endoscopic Scissors
8. Randomized Clinical Trial of OrbusNeichs Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
9. DiFUSION Technologies Completes Successful Antimicrobial Implant Animal Trial
10. IDEV Technologies Completes $46 Million Preferred Stock Financing With Piper Jaffray and Additional Strategic Investor
11. SAFC® Completes Expansion of High-Potency Fermentation Capabilities at Israel Site
Post Your Comments:
(Date:11/25/2015)... 25, 2015 Research and Markets ( ... Market - Global Forecast to 2020" report to ... accounting for 37.21% of the total market share in ... region is projected to growth at the highest ... attributed primarily to the fast growing water, industrial gas ...
(Date:11/24/2015)... November 25, 2015 The hope ... repeated failure of IVF cycles. After failure of over ... and had lost all hopes that she would be able to conceive ever. ... child conceived after failure of over 15 IVF cycles. ... before they decided to take one last attempt with Gaudium IVF ...
(Date:11/24/2015)... , Nov. 24, 2015  Natera, ... in non-invasive genetic testing and the analysis ... it will present at the 27 th ... December 2, 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, Ph.D., ... financial results, business activities and financial outlook. ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 25, 2015 , ... Privately owned Contract Development and Manufacturing ... its current state of the art research, development and manufacturing facility outside of ... manufacturing capacity as well as to support its clients’ growing research and development ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Many people know ... fuzzy-headedness, weight gain, cold hands, and dry skin. But many people who find their ... and exercise regimen instead of their thyroid, especially if they don’t have any of ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in ... involving adult stem cell therapies to patients with chronic degenerative medical conditions. Now, ... a Registered Trademark (RTM). , Organizations are required to hold a registered trademark ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... prices in an early celebration of the early holiday shopping season. Starting Wednesday ... each (normally $33.95 ea). Black Friday promotional pricing is in addition to any ...
(Date:11/24/2015)... ... November 24, 2015 , ... Eric C. Seidel, DMD ... benefits of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser technology ... by a dentist in Gettysburg, PA . From routine visits to cosmetic ...
Breaking Medicine News(10 mins):